European Patent Office Upholds Introgen Patent

Law360, New York (November 13, 2003, 12:00 AM EST) -- Introgen Therapeutics Inc. said its patent on p53 therapy was upheld by the European Patent Office after being challenged by Schering-Plough Corp.

Earlier this year, Schering-Plough filed an opposition against the issuance of the European patent directed to "combination therapy with p53 and conventional chemotherapy and/or radiation."

This is the third successful outcome over a period of three years in oppositions involving Schering-Plough, Introgen said in a statement.

The patent, exclusively licensed to Introgen from The Board of Regents of The University of Texas System, covers...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.